1309832-48-1

Basic information

• Product Name: 2-bromo-1-fluoro-3,5-dinitrobenzene
• Synonyms: 2-bromo-1-fluoro-3,5-dinitrobenzene
• CAS NO: 1309832-48-1
• Molecular Weight: 264.995
• Mol File: 1309832-48-1.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-bromo-1-fluoro-3,5-dinitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-1-fluoro-3,5-dinitrobenzene(1309832-48-1)
• EPA Substance Registry System: 2-bromo-1-fluoro-3,5-dinitrobenzene(1309832-48-1)

Safety Data

• Hazardous Substances Data: 1309832-48-1(Hazardous Substances Data)

Upstream product

• 2265-90-9 2-hydroxy-1,5-dinitro-3-fluorobenzene 
• 367-12-4 2-fluorophenol 

Downstream Products

• 1309832-49-2 2-bromo-3-fluoro-5-nitroaniline 
• 1309833-31-5 4-bromo-3-fluoro-5-nitroaniline 
• 1356493-53-2 4-cyclopropyl-3-fluoro-5-(1H-tetrazol-1-yl)benzenamine 
• 1356493-52-1 1-(2-cyclopropyl-3-fluoro-5-nitrophenyl)-1H-tetrazole 
• 1356493-33-8 N₂-(4-cyclopropyl-3-fluoro-5-(1H-tetrazol-1-yl)phenyl)-5-fluoro-N₄-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine 
• 1356493-32-7 2-(4-cyclopropyl-3-fluoro-5-(1H-tetrazol-1-yl)phenylamino)-4-(2,2,6,6-tetramethylpiperidin-4-ylamino)pyrimidine-5-carbonitrile 
• 1309832-54-9 1-(5-Amino-2-cyclopropyl-3-fluorophenyl)-4-methyl-5H-tetrazol-5-one 
• 1309832-53-8 1-(2-Cyclopropyl-3-fluoro-5-nitrophenyl)-4-methyl-5H-tetrazol-5-one 
• 1309832-52-7 1-(2-cyclopropyl-3-fluoro-5-nitrophenyl)-4,5-dihydro-5H-tetrazol-5-one 
• 1309832-51-6 2-Cyclopropyl-3-fluoro-5-nitrophenylisocyanate 
• 1309832-50-5 2-cyclopropyl-3-fluoro-5-nitroaniline 

Relevant articles and documents

Small molecules enhance functional O-mannosylation of Alpha-dystroglycan

Alpha-dystroglycan (α-DG), a highly glycosylated receptor for extracellular matrix proteins, plays a critical role in many biological processes. Hypoglycosylation of α-DG results in various types of muscular dystrophies and is also highly associated with progression of majority of cancers. Currently, there are no effective treatments for those devastating diseases. Enhancing functional O-mannosyl glycans (FOG) of α-DG on the cell surfaces is a potential approach to address this unmet challenge. Based on the hypothesis that the cells can up-regulate FOG of α-DG in response to certain chemical stimuli, we developed a cell-based high-throughput screening (HTS) platform for searching chemical enhancers of FOG of α-DG from a large chemical library with 364,168 compounds. Sequential validation of the hits from a primary screening campaign and chemical works led to identification of a cluster of compounds that positively modulate FOG of α-DG on various cell surfaces including patient-derived myoblasts. These compounds enhance FOG of α-DG by almost ten folds, which provide us powerful tools for O-mannosylation studies and potential starting points for the development of drug to treat dystroglycanopathy.

FACTOR XIa INHIBITORS

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma Kallikrein.

PROTEIN KINASE C INHIBITORS AND USES THEREOF

This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.